Dolat Capital: Divi’s Labs’ Growth Momentum Continues In Q2, More Capex To Meet Demand
Tablets pass through a blister pack packaging machine inside a pharmaceutical laboratories a(Photographer: Martin Leissl/Bloomberg)

Dolat Capital: Divi’s Labs’ Growth Momentum Continues In Q2, More Capex To Meet Demand

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital Report

Divi’s Laboratories Ltd. reported robust Q2 driven by volume growth across the product portfolio as the current quarter does not reflect any significant Covid-19 related sales.

Debottlenecking of units, backward integration, efficient technologies implementation and favourable raw materials costs led to gross margin expansion at 67%.

Management indicated that the H1 growth is sustainable and is driven by high visibility on order-book.

Click on the attachment to read the full report:

Dolat Capital Divis Laboratories Q2FY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.